EDITAS MEDICINE INC (EDIT) Stock Price, Quote, News and Overview
NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD
EDIT Quote, Performance and Key Statistics
1.56
0 (0%)
The current stock price of EDIT is 1.56 USD. In the past month the price increased by 20%. In the past year, price decreased by -70.68%.
EDIT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About EDIT
Company Profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Company Info
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 265
Company Website: https://www.editasmedicine.com/
Investor Relations: https://ir.editasmedicine.com
Phone: 16174019000
EDITAS MEDICINE INC / EDIT FAQ
What is the stock price of EDITAS MEDICINE INC today?
The current stock price of EDIT is 1.56 USD.
What is the ticker symbol for EDITAS MEDICINE INC stock?
The exchange symbol of EDITAS MEDICINE INC is EDIT and it is listed on the Nasdaq exchange.
On which exchange is EDIT stock listed?
EDIT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EDITAS MEDICINE INC stock?
21 analysts have analysed EDIT and the average price target is 3.83 USD. This implies a price increase of 145.19% is expected in the next year compared to the current price of 1.56. Check the EDITAS MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EDITAS MEDICINE INC worth?
EDITAS MEDICINE INC (EDIT) has a market capitalization of 130.59M USD. This makes EDIT a Micro Cap stock.
How many employees does EDITAS MEDICINE INC have?
EDITAS MEDICINE INC (EDIT) currently has 265 employees.
What are the support and resistance levels for EDITAS MEDICINE INC (EDIT) stock?
EDITAS MEDICINE INC (EDIT) has a resistance level at 1.57. Check the full technical report for a detailed analysis of EDIT support and resistance levels.
Is EDITAS MEDICINE INC (EDIT) expected to grow?
The Revenue of EDITAS MEDICINE INC (EDIT) is expected to decline by -75.47% in the next year. Check the estimates tab for more information on the EDIT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EDITAS MEDICINE INC (EDIT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EDIT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EDIT, evaluating the profitability, health, valuation and growth aspects
- EDITAS MEDICINE INC (EDIT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EDITAS MEDICINE INC (EDIT) Sales and EPS estimates to see what analysts future expectations are.
- EDITAS MEDICINE INC (EDIT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EDITAS MEDICINE INC (EDIT) Insider and Institutional Ownership to learn about the owners and their transactions.
- EDITAS MEDICINE INC (EDIT) Stock Chart to make your own analysis
- EDITAS MEDICINE INC (EDIT) Latest news and press-releases to stay up to date.
Does EDITAS MEDICINE INC (EDIT) stock pay dividends?
EDIT does not pay a dividend.
When does EDITAS MEDICINE INC (EDIT) report earnings?
EDITAS MEDICINE INC (EDIT) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of EDITAS MEDICINE INC (EDIT)?
EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).
What is the Short Interest ratio of EDITAS MEDICINE INC (EDIT) stock?
The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 16.69% of its float. Check the ownership tab for more information on the EDIT short interest.
EDIT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is a bad performer in the overall market: 81.83% of all stocks are doing better.
EDIT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT may be in some trouble as it scores bad on both profitability and health.
EDIT Financial Highlights
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS decreased by -40.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.41% | ||
| ROE | -176.57% | ||
| Debt/Equity | 0.39 |
EDIT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 70% to EDIT. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 46.08% and a revenue growth -75.47% for EDIT